High Resolution Non-Gadolinium CEMRA in Renal Failure: Initial Results in Pediatric Patients at 3.0T
J. Paul Finn 1 , Sarah N Khan 1 , Aarti Luhar 1 , Theodore Hall 1 , Stanislas Rapacchi 1 , Fei Han 1 , Peng Hu 1 , Yutaka Natsuaki 2 , and Isidro Salusky 3
Radiology, UCLA, Los Angeles, California,
Healthcare, California, United States,
UCLA, California, United States
Purpose: We report our initial findings with ferumoxytol
for non-Gd CEMRA at 3.0T in children with renal failure.
Methods: 9 patients aged 6 days to 14 years were studied
on a Siemens TIM Trio system. Multiple CEMRA phases were
acquired up to 30 minutes following injection and
measurements of SNR and CNR in the thoracic aorta and
inferior vena cava (IVC) were recorded at each phase.
Phantom measurements of T1 and T2* relaxivity were made
at 3.0T. Results: The T1 relaxivity was 9.0 mM-1s-1 and
the T2 relaxivity was 90 mM-1s-1. CNR measurements in
patients confirmed that the intravascular signal in the
ferumoxytol group remained high and stable to the last
measurements, up to 35 minutes post injection, whereas
the signal in the control group fell off with time.
Conclusion and Discussion: Initial results with
ferumoxytol are highly encouraging for CEMRA in children
with renal failure.
This abstract and the presentation materials are available to members only;
a login is required.